RTM Vital Signs

What RTM Vital Signs does

RTM Vital Signs, LLC is a Philadelphia-based medical device company developing AI-driven, wearable continuous respiratory and cardiac monitoring systems. Its flagship product, the RTMsense Respiratory Monitoring System (RMS GEN I), uses an ultra-sensitive stethoscope placed on the patient's trachea to capture real-time tidal volume, respiratory rate, and calculated minute ventilation, with onboard processing, wireless data transfer to a hub/tablet, and predictive cloud analytics to identify pre-symptomatic respiratory compromise. RMS GEN I received FDA 510(k) clearance on July 22, 2025 and FDA Breakthrough Device Designation, supported by 10 issued U.S. patents and an exclusive worldwide perpetual license to underlying sensing technology from Thomas Jefferson University.

The company's commercial focus is U.S. hospitals and post-operative/general-ward care for adult patients receiving opioids, with planned pilots in nursing homes and a large NIH/NIDA-funded clinical trial (award R44DA059491) targeting opioid-induced respiratory depression. Secondary verticals include fitness, industrial safety, defense, and veterinary medicine. A second product, the RTMpulse Cardiac Monitoring System (CMS), is a long-term implantable blood pressure and ECG sensor protected by 13 issued patents and currently in the prototype/canine-validation phase.

RTM operates a direct enterprise sales model with quote-based hardware pricing (RTMpod electronics, RTMhub, RTMpack batteries) plus recurring revenue from RTMwear disposable carriers sold in sealed replenishment packs (each supporting up to 72 hours of monitoring). Digital monitoring services are delivered through the RTMpulse multi-user software platform on a credentialed, role-based basis. The company is privately held as an LLC, has 1-10 employees, and has been funded to date primarily by non-dilutive NIH grants and approximately $455K of disclosed angel equity.

Name

RTM Vital Signs

Legal name

RTM Vital Signs, LLC

Website

https://rtmvitalsigns.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

RTM Vital Signs is a Philadelphia-based medical device company that has developed an FDA 510(k)-cleared, AI-driven wearable system for continuous respiratory rate monitoring in adult hospital patients, with a pipeline implantable cardiac monitor and secondary fitness, defense, and veterinary applications.

Ownership category

akta.pro rank

Product category

Medical Devices — Wearable Patient Monitoring

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

akta.pro secondary industry

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Wearable respiratory monitoring
• Continuous patient monitoring
• Cardiac monitoring devices
• AI medical devices
• Vital sign monitoring

Headquarters

HQ city

Fort Washington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Hardware device sales (RTMsense): Sale of the RTMsense Respiratory Monitoring System hardware, comprising the RTMpod electronic device, RTMwear disposable carriers, RTMpack rechargeable batteries, and RTMhub monitor/charging hub. Targets hospital and clinical research settings.
2. Recurring disposable replenishment packs: Recurring revenue from RTMwear disposable carriers sold in sealed replenishment packs. Each carrier supports up to 72 hours of monitoring, creating a consumable revenue stream tied to patient monitoring volume.
3. Digital monitoring services (RTMpulse multi-user): Digital services providing credentialed multi-user remote patient monitoring, status notifications, and role-based software access (Admin, Doctor, Clinician, Patient, Caregiver). Indicates an emerging subscription/managed-service revenue stream.
4. NIH grant funding (non-dilutive): Non-dilutive research funding from the National Institutes on Drug Abuse (NIDA) under award number R44DA059491, supporting an NIH-funded clinical trial to detect and predict opioid-induced respiratory depression (OIRD). RTM has also been awarded 2 NIH Grants per company materials.
5. Licensed technology inbound (TJU): Some RTM technology is based on concepts exclusively licensed in perpetuity on a worldwide basis from Thomas Jefferson University (TJU). Implies ongoing royalty obligations to TJU as commercial sales scale.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

RTM Vital Signs develops and commercializes AI-driven wearable medical devices that continuously monitor respiratory and cardiac function. Its flagship product, the RTMsense Respiratory Monitoring System (RMS GEN I), is an FDA 510(k)-cleared wearable placed on the trachea that uses an ultra-sensitive stethoscope with onboard processing and cloud analytics to continuously measure respiratory rate, tidal volume, and minute ventilation. The company also offers the RTMpulse Cardiac Monitoring System (CMS), a long-term implantable blood pressure and ECG sensor with predictive algorithms, supported by 13 issued patents.

Product overview

RTM Vital Signs offers a portfolio of two core wearable/implantable medical device product lines, both built on proprietary cost-effective sensor technology and AI-driven diagnostic algorithms. The portfolio is structured as a platform-plus-modules architecture: RTMsense (RMS) is the flagship respiratory monitoring wearable, FDA 510(k)-cleared (RMS GEN I) and composed of the RTMpod electronic module, the disposable RTMwear carrier, swappable RTMpack batteries, the RTMhub pairing/display/charging hub, and the RTMpulse multi-user monitoring software service for clinicians and caregivers. The second core product, RTMpulse Cardiac Monitoring System (CMS), is a long-term implantable blood pressure and ECG sensor with predictive algorithms for hypertension management and adverse cardiac event prediction; it is currently in the prototype/validation phase (in-vitro and in-vivo canine studies completed) and is supported by 13 issued patents. The two systems address the largest areas of healthcare concern and cost — cardiovascular and respiratory health — and the company also identifies applications in fitness, industrial safety, military, and veterinary medicine.

Differentiator

Problem solved

Functional benefit

Brands

• RTMsense: Respiratory Monitoring System (RMS) — a breakthrough AI-driven wearable respiratory monitoring device that continuously measures respiratory rate; received FDA 510(k) clearance for RMS GEN I on July 22, 2025.
• RTMpulse

Products and services

• RTMsense Respiratory Monitoring System (RMS) RTMsense is an AI-driven, wearable respiratory monitoring device placed on the trachea that continuously measures tidal volume, respiratory rate, and calculated minute ventilation. RMS GEN I is FDA 510(k) cleared and intended for use by healthcare professionals in hospitals, ambulatory, and clinical research settings to detect pre-symptomatic respiratory compromise as an adjunct to other clinical information sources.
• RTMpulse Cardiac Monitoring System (CMS) Long-term, outpatient implantable blood pressure sensor that continuously measures the full arterial blood pressure waveform and ECG; sensor data feeds predictive algorithms to improve diagnostics and medication dosing for hypertension and cardiac issues, aiming to predict and prevent adverse cardiac events. Targeted at cardiac patients requiring continuous monitoring.

Quantifiable outcome

• Respiratory depression occurs in up to 46% of patients receiving opioids on the hospital general care floor
• +4 more outcomes

Segments7 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• EarlySense: Contact-free continuous monitoring company (InSight) with FDA-cleared products for hospital and post-acute settings. Adjacent technology approach (piezoelectric bed sensor) competing for the same clinical workflow of detecting patient deterioration.
• Biotricity: Wearable remote cardiac and vital-sign monitoring company (Bioflux) for clinical and remote-patient-monitoring applications. Comparable wearable + cloud + AI architecture and overlapping hospital-to-home monitoring positioning.
• Nonin Medical: Specialist in pulse oximetry and wearable vital-sign sensors with a clinical and ambulatory footprint. Comparable wearable hardware technology and overlapping respiratory/customer segments in hospitals and home care.
• Spire Health: Wearable respiratory monitoring company focused on chronic disease management (COPD, asthma) and sleep. Comparable form factor strategy (small adhesive wearable) and overlapping minute-ventilation / tidal-volume measurement claim.

Broad incumbents

• Masimo: Established patient-monitoring incumbent whose rainbow SET platform includes acoustic respiration sensing and continuous SpHb monitoring. Competes with RTM in the hospital continuous-monitoring category and has the installed base and clinical-sales reach that RTM lacks.
• Philips: Major patient-monitoring incumbent (IntelliVue, Biosensor) with continuous vital-sign solutions sold into hospitals globally. Comparable channel position and overlapping clinical use cases for respiratory monitoring on the general ward.
• Medtronic: Dominant medtech incumbent with capnography-based respiratory monitoring (Microstream, Capnostream) and a broad patient-monitoring business. Represents both the primary competitive threat and a likely strategic acquirer for RTM's respiratory franchise.
• Vyaire Medical: Respiratory care company (Bellavista ventilators, capnography) serving hospitals and ICUs. Comparable customer base in respiratory care and overlapping continuous monitoring use cases for post-operative and general ward patients.
• GE HealthCare: Large incumbent in hospital patient monitoring (CARESCAPE, Portrait) with established relationships across U.S. hospital systems. Comparable enterprise sales motion and overlapping respiratory-monitoring use cases.

Direct peers

• Respiratory Motion: Direct competitor developing wearable, continuous respiratory monitoring technology (ExSpiron) that, like RTMsense, measures tidal volume and respiratory rate in non-intubated patients to detect respiratory compromise. Closest product analog to RTM's RTMsense.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rtm-vital-signs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RTM Vital Signs